Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

Phase 1/2 Unknown 39 enrolled Xi'an Xintong Pharmaceutical Research Co.,Ltd. The First Hospital of Jilin University · collab

NaSequentialOpen-labelTreatment

Summary

An open-label, multi-dose clinical trial design was used to investigate the combination of MB07133 injection combined with Sintilimab in the treatment of primary liver cancer in phase I/IIa studies, including two phases of dose escalation and dose expansion，in order to evaluate the safety and efficacy of MB07133 injection combined with Sintilimab.

Timeline

Start: 2022-01-18
Primary completion: 2024-07-31
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MB07133	Small molecule	600 mg/m2	Other
Subject	MB07133	Small molecule	1200 mg/m2	Other
Subject	MB07133	Small molecule	1800 mg/m2	Other
Subject	Sintilimab	Monoclonal antibody	200 mg	Other

Indications

No indication recorded.